EA202091597A1 - Способы и композиции для лечения апноэ сна - Google Patents

Способы и композиции для лечения апноэ сна

Info

Publication number
EA202091597A1
EA202091597A1 EA202091597A EA202091597A EA202091597A1 EA 202091597 A1 EA202091597 A1 EA 202091597A1 EA 202091597 A EA202091597 A EA 202091597A EA 202091597 A EA202091597 A EA 202091597A EA 202091597 A1 EA202091597 A1 EA 202091597A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
sleep apnea
compositions
treatment
nri
Prior art date
Application number
EA202091597A
Other languages
English (en)
Inventor
Лоуренс Дж. Миллер
Барри Воль
Уолтер Дж. Лунсманн
Original Assignee
Апнимед, Инк. (Делавэр)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Апнимед, Инк. (Делавэр) filed Critical Апнимед, Инк. (Делавэр)
Publication of EA202091597A1 publication Critical patent/EA202091597A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В общем, изобретение относится к фармацевтическим композициям, включающим (R)-оксибутинин и ингибитор обратного захвата норадреналина (NRI), и к способам лечения апноэ сна, включающим введение (R)-оксибутинина и ингибитора обратного захвата норадреналина (NRI). В некоторых вариантах осуществления NRI представляет собой атомоксетин.
EA202091597A 2018-01-30 2019-01-30 Способы и композиции для лечения апноэ сна EA202091597A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862623892P 2018-01-30 2018-01-30
PCT/US2019/015781 WO2019152475A1 (en) 2018-01-30 2019-01-30 Methods and compositions for treating sleep apnea

Publications (1)

Publication Number Publication Date
EA202091597A1 true EA202091597A1 (ru) 2020-10-22

Family

ID=65441079

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091597A EA202091597A1 (ru) 2018-01-30 2019-01-30 Способы и композиции для лечения апноэ сна

Country Status (14)

Country Link
US (2) US11911351B2 (ru)
EP (1) EP3746126A1 (ru)
JP (2) JP7422666B2 (ru)
KR (1) KR20200115598A (ru)
CN (1) CN111670050A (ru)
AU (1) AU2019214891A1 (ru)
BR (1) BR112020015316A2 (ru)
CA (1) CA3089712A1 (ru)
EA (1) EA202091597A1 (ru)
IL (1) IL276247A (ru)
MA (1) MA52861A (ru)
MX (1) MX2020008086A (ru)
SG (1) SG11202007226UA (ru)
WO (1) WO2019152475A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240042261A (ko) * 2017-04-28 2024-04-01 더 브리검 앤드 우먼즈 하스피털, 인크. 수면 무호흡을 치료하기 위한 방법 및 조성물
US20220362221A1 (en) * 2019-11-04 2022-11-17 Apnimed, Inc. (Delaware) Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea
JP2024508498A (ja) * 2021-03-04 2024-02-27 アプニメッド，インコーポレイテッド（デラウェア） 睡眠時無呼吸の治療における使用のためのレボキセチン及びムスカリン受容体拮抗薬（ｍｒａ）の組み合わせ
WO2022204228A1 (en) * 2021-03-24 2022-09-29 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
KR20240004600A (ko) 2021-05-04 2024-01-11 애프니메드, 인코포레이티드 (델라웨어) (r)-옥시부티닌 d-말레이트의 고체 형태
BR112023026158A2 (pt) * 2021-06-17 2024-03-05 Apnimed Inc Delaware Inibidores da recaptação de norepinefrina para tratamento da apneia do sono
TW202342033A (zh) 2021-12-22 2023-11-01 德商拜耳廠股份有限公司 用於治療睡眠呼吸中止之α２－腎上腺素受體亞型Ｃ（α－２Ｃ）拮抗劑與正腎上腺素再吸收抑制劑之組合
TW202342011A (zh) 2021-12-22 2023-11-01 德商拜耳廠股份有限公司 用於治療睡眠呼吸中止之α２－腎上腺素受體亞型Ｃ（α－２Ｃ）拮抗劑與蕈毒鹼受體拮抗劑之組合
WO2023219991A1 (en) * 2022-05-13 2023-11-16 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL267508A (ru) 1960-07-26
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
AU714270B2 (en) 1995-10-24 1999-12-23 Gruenenthal Gmbh Method of inhibiting sleep apnea
CN1396829A (zh) * 2000-02-24 2003-02-12 法玛西雅厄普约翰美国公司 新的药物联合形式
WO2002089843A1 (en) 2001-03-13 2002-11-14 Millenium Pharmaceuticals, Inc. Methods for treating or preventing cardiovascular disorders by modulating metalloprotease function
US20030060513A1 (en) 2001-09-27 2003-03-27 Arneric Stephen P. Pharmaceutical composition
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US20040235925A1 (en) 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US20050009862A1 (en) 2003-04-25 2005-01-13 Sabounjian Luann Method for promoting uninterrupted sleep by administration of trospium chloride
ATE426405T1 (de) 2003-12-22 2009-04-15 Acadia Pharm Inc Amino-substituierte diarylaa,ducyclohepten- analoga als muscarinische agonisten und verfahren zur behandlung von neuropsychiatrischen erkrankungen
US20060039866A1 (en) 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
WO2006055854A2 (en) 2004-11-17 2006-05-26 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtazapine treatment
EP1833467B1 (en) 2004-12-20 2016-08-03 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
CA2646729A1 (en) 2005-03-21 2006-09-28 Dov Pharmaceutical, Inc. Methods and compositions for the treatment of urinary incontinence
EP1868602A1 (en) 2005-04-15 2007-12-26 The Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
US8364407B2 (en) 2005-07-21 2013-01-29 The Invention Science Fund I, Llc Selective resonance of chemical structures
FR2889811B1 (fr) 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
WO2008066750A1 (en) 2006-11-22 2008-06-05 Seaside Therapeutics, Llc Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism
WO2008122019A1 (en) 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
NZ580250A (en) 2007-04-09 2012-05-25 Sunovion Pharmaceuticals Inc Methods and compositions comprising desmethylvenlafaxine or duloxetine for treating sleep-related breathing disorders
US8415390B2 (en) 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US20090048233A1 (en) 2007-08-16 2009-02-19 Cypress Biosciences, Inc. Enhancing the Tolerability of a Seratonin Antagonist and a NSRI, a SNRI or a RIMA by Using Them in Combination
BRPI0821761A2 (pt) 2007-12-21 2015-06-16 Eurand Inc Composições de comprimidos de desintegração oral de temazepam
US20100204058A1 (en) 2009-01-28 2010-08-12 Howard Yuan-Hao Chang Profiling for Determination of Response to Treatment for Inflammatory Disease
MX2012011395A (es) 2010-04-01 2013-02-26 Theravida Inc Metodos de mejoramiento de la calidad del sueño.
EP2672972B1 (en) 2011-01-28 2020-11-04 Pfantastic Medical Research Institute, LLC Methods for treating obstructive sleep apnea
JP2012176958A (ja) 2012-04-20 2012-09-13 Watson Pharmaceuticals Inc （ｒ）−オキシブチニンおよび（ｒ）−デスエチルオキシブチニンによる平滑筋機能亢進の処置
CA2904310C (en) 2013-03-05 2022-07-12 Requis Pharmaceuticals Inc. Preparations for the treatment of sleep-related respiratory disorders
AU2015335375B2 (en) 2014-10-24 2020-09-10 Launx Biomedical Co., Ltd. Use of azelnidipine in preparing medicinal composition for treating cancers
HUE047169T2 (hu) 2015-04-27 2020-04-28 Arena Pharm Inc 5-HT2C receptor agonisták és készítmények és felhasználási eljárások
WO2017015309A1 (en) 2015-07-22 2017-01-26 John Hsu Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof
US20180235934A1 (en) 2015-08-18 2018-08-23 Massachusetts Institute Of Technology Noradrenergic drug treatment of obstructive sleep apnea
KR20240042261A (ko) * 2017-04-28 2024-04-01 더 브리검 앤드 우먼즈 하스피털, 인크. 수면 무호흡을 치료하기 위한 방법 및 조성물
CN111818946A (zh) 2018-01-31 2020-10-23 国家儿童医院研究所 2c型肢带型肌营养不良的基因疗法
SG11202108225QA (en) 2019-02-08 2021-08-30 Brigham & Womens Hospital Inc Methods and compositions for treating sleep apnea

Also Published As

Publication number Publication date
US11911351B2 (en) 2024-02-27
US20210038541A1 (en) 2021-02-11
US20220378724A1 (en) 2022-12-01
JP2021516218A (ja) 2021-07-01
IL276247A (en) 2020-09-30
CA3089712A1 (en) 2019-08-08
MX2020008086A (es) 2021-02-15
MA52861A (fr) 2021-05-05
KR20200115598A (ko) 2020-10-07
SG11202007226UA (en) 2020-08-28
WO2019152475A1 (en) 2019-08-08
JP2023181322A (ja) 2023-12-21
JP7422666B2 (ja) 2024-01-26
CN111670050A (zh) 2020-09-15
EP3746126A1 (en) 2020-12-09
BR112020015316A2 (pt) 2020-12-08
AU2019214891A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
EA202091597A1 (ru) Способы и композиции для лечения апноэ сна
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
NZ734516A (en) Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n’-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
TN2017000119A1 (en) Indole carboxamides compounds useful as kinase inhibitors
EA201491773A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата
EA201990951A1 (ru) Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
EA201892657A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201490748A1 (ru) Лечение рассеянного склероза комбинацией лахинимода и финголимода
BR112015005117A2 (pt) métodos de tratamento da doença de alzheimer e suas composições farmacêuticas
MX2015012760A (es) Composicion farmaceutica que comprende un activador de ampk y un agente serotonergico y metodos de uso de la misma.
PH12020551597A1 (en) Treatment of hidradenitis suppurativa using jak inhibitors
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
CO6341486A2 (es) Tratamiento y profilaxis de amiloidosis
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA200601746A1 (ru) Применение ротиготина для лечения и предупреждения синдрома "паркинсонизм-плюс"
EA201990425A1 (ru) Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
EA201300988A1 (ru) Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол
EA201590726A1 (ru) Лахинимод для уменьшения таламического поражения при рассеянном склерозе
MX2022007113A (es) Inhibidores de la desmetilasa de la histona especifica de la lisina para el tratamiento de las neoplasias mieloproliferativas.
BR112016013754A2 (pt) Recaptação de serotonina-norepinefrina inibidores (irsns) e combinações dos ligantes do receptor sigma
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
EA201892098A1 (ru) Соединение, обладающее ингибирующей мутантную idh активностью, способ его получения и применения